9th Spring Meeting


  • Sponsors:
  • Exhibits:
  • Media Partners:

Speakers

  • Lawrence C. Thompson, PhD

    Principal Scientist and Group Leader, BioTherapeutics Pharm Sci, Analytical Research and Development

    Pfizer, Inc.

    Process Development and Analytical Characterization of the Adenovirus and Plasmid Components for the Vaccine-Based Immunotherapy Regimen

  • Young Jik Kwon, PhD

    Professor, Department of Pharmaceutical Sciences; Department of Chemical Engineering and Materials Science

    University of California, Irvine (UCI)

    Chemically Induced Extracellular Vesicles for Versatile Therapies via Facile and Scalable Production and Purification

  • Jacques Galipeau, MD

    Associate Dean for Therapeutics Development; Director, Program for Advanced Cell Therapy

    University of Wisconsin-Madison

    Cellular Cryoinjury and Potency – the Mesenchymal Stromal Cell Paradigm

  • Peter Gagnon

    Chief Scientific Officer

    BIA Separations

    Emerging Methods for Exosome Purification and Process Monitoring

  • Mania Ackermann, PhD

    Postdoctoral Fellow, Project Leader, REBIRTH Unit, Translational Hematology of Congenital Diseases, Institute of Experimental Hematology

    Hannover Medical School

    iPSC Technology: New Avenues for Blood Farming and Cell-Based Therapies

  • Donald L. Jarvis, PhD

    Professor, Molecular Biology

    University of Wyoming

    An Update on Glycoengineering and Adventitious Viruses in the Baculovirus-Insect Cell System

  • Hazel Aranha, PhD

    Virus Safety and Clearance, SME

    Sartorius Stedim North America Inc.

    Raw Materials Management: A Cornerstone for Risk Mitigation in Virus Safety Assurance of Biopharmaceuticals

  • Peter Pushko, PhD

    President and Chief Scientific Officer

    Medigen, Inc.

    Development of Multi-Subtype VLPs (msVLPs) as Broadly Protective Influenza Vaccines

  • Karen Doucette

    Director of Operations

    ACF Bioservices

    Validating GMP-Compliant In Vitro Relative Potency Assays for Cell and Gene Therapy Products

  • Alfred Luitjens

    Director Cell Technology

    Batavia Biosciences

    Highly Intensified, Low-Cost Vaccine Manufacturing Platform

  • Peter Czermak

    Professor of Bioprocess/Biochemical Engineering

    Technische Hochschule Mittelhessen, Fachbereich LSE

    Oncolytic Measles Virus Manufacturing: Linking Upstream and Downstream Strategies

  • Michelet Dorceus

    Bioprocess Field Application Manager

    Eppendorf North America

    High-Density Vero Cell Perfusion Culture in Single-Use Vessels

  • Suitability and Perspectives of Different Insect Cell Factories for the Production of Antimicrobial Peptides

  • Brian Hampson

    VP Global Manufacturing Sciences & Technology

    Hitachi Chemical Advanced Therapeutics Solutions, LLC

    Automation in Cell Therapy — What Problem(s) are We Trying to Solve?

  • Imre Berger, PhD

    Professor & Director, BrisSynBio Centre for Synthetic Biology

    University of Bristol

    MultiBac: From Multiprotein Complex Structures to Synthetic Viral Nanosystems (SVNs)

  • Debra A. Webster, PhD

    Director, Advanced Therapy Medicinal Product Development, Regulatory Sciences

    Cardinal Health

    Keeping Pace with Product Development: Synergies Between Quality, Nonclinical, and Clinical Programs

  • Monique M. van Oers, PhD

    Professor, Laboratory of Virology

    Wageningen University

    Walking with Insects: How Viruses Manipulate Insect Behaviour

  • Claes Gustafsson, PhD

    Co-Founder, CCO

    ATUM

    Engineering Better Viral Vectors Using Machine Learning and Synthetic Biology

  • Sandra K. McNorton

    Senior R&D Scientist

    MilliporeSigma

    Optimizing Cell Culture Medium for Cell Growth and Virus Productivity

  • Olli H. Laitinen, PhD

    Adjunct Professor, University Researcher

    University of Tampere

    Optimizing the Baculovirus Expression System for Coxsackievirus VLP-Vaccine Production

  • Francis Karanu, PhD

    Director of Animal Health & Senior Scientist

    Likarda, LLC

    Comparing Characterization Assays Across Different Cell Therapies

  • Mark Flower

    Vice President, Business Development & Strategic Partnerships

    Be The Match BioTherapies, National Marrow Donor Program (NMDP)

    Mitigating Supply Chain Challenges in Cell Therapies, and the Importance of Quality Apheresis — A Critical Starting Material

  • Michael Day, PhD

    Director Regulatory Science, Co-Head Complex Biologics

    Voisin Consulting Life Sciences

    Regulatory and Development Strategies for Cell Therapies

  • Laura A. Palomares, ScD

    Researcher and Professor

    Universidad Nacional Autónoma de México (UNAM)

    AAV and Baculovirus Vectors for the Treatment of Hyperammonemia Caused by Liver Failure

  • Henry de Malmanche

    PhD Candidate

    University of Queensland

    Baculovirus Biopesticides: Progress Towards Reaching Commercially Viable Yields of Bioreactor-Produced Occlusion Bodies by Exploring Gene Knock-Ins and CRISPR/Cas9 Knock-Outs of Production Cell Lines

  • Chun Fang Shen, PhD

    Senior Research Council Officer, Cell Culture Scale-up, Life Sciences, NRC Human Health Therapeutics Research Center

    National Research Council Canada (NRC)

    Development of Suspension-Adapted Vero Cell Culture Technology for Viral Vaccine Production

  • Anthony Leyme, PhD

    Scientist II, Technical Development, Analytical Bioassay Development

    Biogen

    In Vitro Approaches to Demonstrating Potency of Gene Therapy Products

  • Linda Lua, PhD

    Director, UQ Protein Expression Facility

    University of Queensland

    Getting the Best Out of Baculovirus Expression Technology for Producing a Diverse Range of Proteins

  • Kevin Kent, PhD

    Scientist IV

    Boehringer Ingelheim Vetmedica, Inc.

    Multivariate Data Analysis for Reduction of Variation in a Viral Vaccine Production Process

  • Arifa S. Khan, PhD

    Supervisory Microbiologist, Office of Vaccines Research and Review

    FDA CBER

    Updated Evaluation of the Sf9 Cell Line

  • Gregory Alberts, PhD

    Global Subject Matter Expert, Pharma Bioscience Solutions

    Lonza Walkersville, Inc.

    Nucleofection: Bench to Clinic to Commercial

  • Development of the 1st World Health Organisation International Standard for Gene Therapy Products

  • Lois Horton

    Process Development Engineer, Gene Therapy Development

    Sanofi Genzyme

    Producer Cell Line for Gene Therapy Development

  • Udo Reichl

    Director, Bioprocess Engineering

    Max-Planck-Institute for Dynamics of Complex Technical Systems

    High Yield Viral Vaccine Production: Process Options and Monitoring

  • Leticia Frizzo da Silva, DVM, PhD

    R&D Project Leader

    Ceva Animal Health, LLC

    Turkey Herpesvirus as a Vector for Poultry Vaccines

  • Chia-Hsing Pi

    PhD Candidate

    University of Minnesota

    Improving the Preservation of PBMC and Purified T-cells

  • Behzad Mahdavi, PhD

    Vice President, Strategic Innovation & Alliances

    Lonza Inc.

    Harness the Power of Exosomes: The Next Revolutionary “Small” Thing in Diagnostics and Regenerative Medicine

  • Robin Levis, PhD

    Deputy Director, Division of Viral Products, Office of Vaccines Research and Review

    FDA CBER

    Historical Perspectives on the Use of Diverse Cell Substrates for Viral Vaccine Manufacturing

  • Cenk Sumen, PhD

    Director, Business Development, BioProduction Division

    Thermo Fisher Scientific

    T-cell Therapies: Building the Next Operating System

  • Amanda K.A. Silva

    CNRS Researcher

    Université Paris Diderot

    Triggering High-Yield Extracellular Vesicle Production for Regenerative Medicine

  • Priya R. Baraniak, PhD

    Senior Director, Business Development

    RoosterBio Inc.

    Manufacturing Solutions Driving Rapid Clinical Translation of hMSCs

  • Eva Rohde

    Head of University Clinic for Blood Group Serology and Transfusion Medicine; Director of GMP Laboratory

    Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU)

    Therapeutic Potency of Stromal Cell Derived Extracellular Vesicles

  • Jamal Meghrous, PhD

    Manager, Upstream Process Development

    Protein Sciences Corporation, A Sanofi Company

    Baculovirus Platform for Rapid Manufacturing of Seasonal Flu Vaccine at Large-Scale

  • Christine Le Bec, PhD

    Head of CMC Analytical

    Généthon

    Strategies and Advances in AAV Vector Characterization: Product-Related Impurities

  • Lindsey Ott, PhD

    Director of Product Innovation

    Likarda, LLC

    3D In Vitro Screening for Cancer Immunotherapies

  • Florian Krammer, PhD

    Associate Professor

    Icahn School of Medicine at Mount Sinai

    The Influenza Virus Neuraminidase as a Vaccine Target

  • Ivan Wall, PhD

    Professor of Regenerative Medicine, Cell and Gene Therapy Bioprocessing, School of Life & Health Sciences

    Aston University

    Bioprocessing of Cells and Exosomes for Regenerative Medicine

  • Anna Kwilas, PhD

    Gene Therapy CMC Product Reviewer

    FDA CBER

    Regulatory Updates for Virus-Based Human Gene Therapy Products

  • Gillian Payne, PhD

    Director, Analytical Development

    bluebird bio Inc.

    Potency Assays for Lentiviral Vectors

  • Romy M. Dalton, PhD

    Operations Manager

    Algenex, Inc.

    Highly Efficient Production of VLP-Based Vaccines by a Bioreactor-Free Novel BEVS Technology

  • Andrew Quigley

    Membrane Protein Laboratory Coordinator/ Group Leader

    Diamond Light Source Ltd

    The Over-Expression of Membrane Proteins for Structural Biology Using Baculovirus

  • Johan Skog

    Chief Scientific Officer

    Exosome Diagnostics, Inc.

    Current State of Exosome-Based Diagnostics

  • Willem "Wian" A. de Jongh, PhD

    CSO

    ExpreS2ion Biotechnologies

    Production of Vaccine Antigens Using Drosophila S2 Insect Cells

  • Martin A. Giedlin, PhD

    VP Technical Operations

    Poseida Therapeutics, Inc.

    Discussion on the Use of Non-Viral Cell Gene Modification for the Generation of CAR T-cells

  • Inês A. Isidro, PhD

    Scientist - Computational Biotechnology, Animal Cell Technology Unit

    Instituto de Biologia Experimental e Tecnológica (iBET)

  • David A. Theilmann, PhD

    Research Scientist, Summerland Research and Development Centre

    Agriculture and Agri-Food Canada

  • Sadik Kassim, PhD

    Chief Scientific Officer

    Mustang Bio, Inc.

  • Gale E. Smith, PhD

    Vice President of Vaccine Development

    Novavax, Inc.

  • Vaughn Tunstall

    Oceanside Site Quality Head

    Genentech, a Member of the Roche Group

  • Marylou G. Gibson, PhD

    General Manager

    Virapur, LLC

  • Darren W. Begley

    Sr. Scientist, Analytical Development

    Ultragenyx Pharmaceutical